Surrozen Inc (SRZN) USD0.0001

Sell:$8.00Buy:$12.00$0.03 (0.28%)

Prices delayed by at least 15 minutes
Sell:$8.00
Buy:$12.00
Change:$0.03 (0.28%)
Deal now
Prices delayed by at least 15 minutes
Sell:$8.00
Buy:$12.00
Change:$0.03 (0.28%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

Key people

Craig C. Parker
President, Chief Executive Officer, Director
Charles O. Williams
Chief Financial Officer, Chief Operating Officer, Company Secretary
Yang Li
Executive Vice President - Research
David J. Woodhouse
Non-Executive Chairman of the Board, Independent Director
Tim Kutzkey
Director
Anna Berkenblit
Independent Director
Eric H. Bjerkholt
Independent Director
Christopher Y. Chai
Independent Director
Click to see more

Key facts

  • EPIC
    SRZN
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US86889P2083
  • Market cap
    $84.87m
  • Employees
    40
  • Shares in issue
    8.46m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.